| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRTX | Common Stock | Sale | -$546K | -1.61K | -1.24% | $338.69 | 128K | 27 Apr 2023 | Direct | F1, F2, F3 |
| transaction | VRTX | Common Stock | Sale | -$566K | -1.67K | -1.3% | $339.43 | 127K | 27 Apr 2023 | Direct | F1, F2, F4 |
| transaction | VRTX | Common Stock | Sale | -$12.9K | -38 | -0.03% | $340.19 | 127K | 27 Apr 2023 | Direct | F1 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022. |
| F2 | Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| F3 | Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99). |
| F4 | Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98). |